USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$10.07M
Market Cap
-
P/E Ratio
-1.26
EPS
$15.60
52 Week High
$2.00
52 Week Low
BASIC MATERIALS
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.3M |
| Total Revenue | $9.5M |
| Cost Of Revenue | $8.2M |
| Costof Goods And Services Sold | $8.2M |
| Operating Income | -$1.6M |
| Selling General And Administrative | $2M |
| Research And Development | $48K |
| Operating Expenses | $2.9M |
| Investment Income Net | - |
| Net Interest Income | $126K |
| Interest Income | $148K |
| Interest Expense | $21K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $153K |
| Income Before Tax | -$1.6M |
| Income Tax Expense | $3.5K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$1.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.6M |
| Ebitda | -$1.4M |
| Net Income | -$1.6M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$2.2M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $153K |
| Capital Expenditures | $227K |
| Change In Receivables | - |
| Change In Inventory | -$251K |
| Profit Loss | - |
| Cashflow From Investment | $418K |
| Cashflow From Financing | $145K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $68K |
| Dividend Payout Common Stock | $68K |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$1.6M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.3M |
| Total Revenue | $9.5M |
| Cost Of Revenue | $8.2M |
| Costof Goods And Services Sold | $8.2M |
| Operating Income | -$1.6M |
| Selling General And Administrative | $2M |
| Research And Development | $48K |
| Operating Expenses | $2.9M |
| Investment Income Net | - |
| Net Interest Income | $126K |
| Interest Income | $148K |
| Interest Expense | $21K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $153K |
| Income Before Tax | -$1.6M |
| Income Tax Expense | $3.5K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$1.6M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.6M |
| Ebitda | -$1.4M |
| Net Income | -$1.6M |
Sector: BASIC MATERIALS
Industry: SPECIALTY CHEMICALS
BioNexus Gene Lab Corp (BGLC), headquartered in Kuala Lumpur, Malaysia, is an innovative biotechnology company focusing on cutting-edge genetic research and therapeutic solutions. Leveraging advanced gene editing and biomanufacturing techniques, BGLC is addressing key healthcare challenges while also enhancing agricultural productivity. With a robust product pipeline and a strong commitment to sustainability and regulatory adherence, BioNexus is well-positioned to capitalize on the increasing global demand for biotechnology advancements, promising significant growth in this dynamic sector.